Davis Capital Management
PCRX icon

Davis Capital Management’s Pacira BioSciences PCRX Stock Holding History

Davis Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$50 Hold
2
– – ﹤0.01% 1134
2026
Q2 		$51 Buy
+2
New +$47 ﹤0.01% 1208

Other funds holding PCRX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $13B AUM 14.15% 1-Year Est. Return
Gagnon Securities
Gagnon Securities New York $577M AUM 61.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Davis Capital Management's PCRX Position: Q3 2026 in Review

Davis Capital Management held its Pacira BioSciences (PCRX) position steady in Q3 2026 at 2 shares worth $50. The position accounts for ﹤0.01% of the portfolio, ranked #1134.

Davis Capital Management first reported a position in PCRX in Q2 2026 and has held it in 2 quarters since. The position peaked at $51 in Q2 2026. 166 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Davis Capital Management held 2 shares of Pacira BioSciences worth $50 as of Q3 2026.
  • Davis Capital Management left its Pacira BioSciences share count unchanged in Q3 2026.
  • Pacira BioSciences made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #1134 holding.
  • Davis Capital Management first reported a position in Pacira BioSciences in Q2 2026 and has held it in 2 quarters since.
  • Davis Capital Management's Pacira BioSciences position peaked at $51 in Q2 2026.
  • 166 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.